NUDT15*4(p.R139H)等位基因的临床可操作性及其与西班牙裔的关联
本研究在1,399例急性淋巴细胞白血病患者中评估NUDT15*4与6-巯基嘌呤耐受性的关联,发现*1/*4患者(均为西班牙裔/拉丁裔)耐受剂量显著低于*1/*1(中位39.0 vs 62.2 mg/m2,P<0.001),验证队列6例*1/*4患者中位耐受剂量38.7 mg/m2,提示需将该变异纳入硫嘌呤剂量算法。
要点
- NUDT15*1/*4患者6-MP耐受剂量显著低于*1/*1,需考虑减量
- *4变异在西班牙裔/拉丁裔中常见,常规药物基因组检测应关注
- 当前CPIC将*4列为功能不确定,本研究支持其临床可操作性
核心结论
- NUDT15*4与6-MP耐受性降低显著相关,支持将其纳入药物基因组学指导的硫嘌呤剂量算法。
研究设计与样本
- 回顾性队列研究纳入1,399例急性淋巴细胞白血病患者,均为硫嘌呤甲基转移酶基因野生型,接受6-MP前线治疗。
- 另设回顾性验证研究,通过常规临床药物基因组学检测识别6例NUDT15*1/*4患者。
主要发现
- NUDT15*1/*4患者(n=16,均自认为西班牙裔/拉丁裔)耐受6-MP中位剂量39.0 mg/m2(IQR 21.2-52.8),显著低于*1/*1患者的62.2 mg/m2(IQR 47.9-71.6),P<0.001。
- 未检出*4纯合子患者。
- 验证队列6例*1/*4患者耐受6-MP中位剂量38.7 mg/m2(IQR 33.7-54.0)。
临床怎么用
- 对西班牙裔/拉丁裔患者进行NUDT15基因分型时,应涵盖*4变异以指导6-MP起始剂量调整。
局限性
- 研究为回顾性设计,*1/*4患者样本量较小(n=16),未检出*4纯合子。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nudix hydrolase 15 (NUDT15) deficiency is strongly associated with thiopurine-induced myelosuppression. Currently, testing for NUDT15 deficiency is based on the genotyping of the most frequent and clinically characterized no-function variants, that is, *2, *3 and *9. The Hispanic/Latino-predominant variant NUDT15 *4 (p.R139H) is classified as "uncertain function" by the Clinical Pharmacogenetics Implementation Consortium, because of insufficient data to ascertain its clinical actionability. In this study, we evaluated the association of NUDT15 *4 with mercaptopurine (6-MP) tolerance in a retrospective cohort of 1,399 patients with acute lymphoblastic leukemia (ALL) of diverse ancestries. All patients were wildtype for thiopurine methyltransferase gene. Patients were treated with 6-MP in the context of ALL frontline clinical trials. The tolerated dose of 6-MP was used to assess drug toxicity during the maintenance phase of ALL therapy. Patients with NUDT15 *1/*4 (n = 16, all of whom self-identified as Hispanic/Latino) tolerated a significantly lower dose of 6-MP than did those with NUDT15 *1/*1: median [interquartile range] of 39.0 [21.2-52.8] mg/m2, vs. 62.2 [47.9-71.6] mg/m2, P value < 0.001. No patient homozygous for *4 was detected. In a separate retrospective validation study, six patients were identified as having NUDT15 *1/*4 by routine clinical pharmacogenetics testing and tolerated a 6-MP median dose of 38.7 mg/m2 (IQR, 33.7-54.0), confirming the need for dose reduction attributed to the NUDT15 *4 variant. These results point to the need to include NUDT15 *4 in pharmacogenetics-guided thiopurine dosing algorithms.
引用
- Maillard M, Nguyen JQ, Yang W, et al. Clinical Actionability of the NUDT15 *4 (p.R139H) Allele and Its Association With Hispanic Ethnicity. Clin Pharmacol Ther. 2024. PMID: 39688234. doi:10.1002/cpt.3501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。